Medical Education Library

The Benefits and Risks of Oral Antiplatelet Therapy in Patients With Acute Coronary Syndrome

Funding for this newsletter series was provided by AstraZeneca

 

The Cardiovascular Insights for Primary Care Physicians eNewsletter Series summarizes key information and data on common cardiovascular issues facing primary care physicians today.

The third eNewsletter, The Benefits and Risks of Oral Antiplatelet Therapy in Patients with Acute Coronary Syndrome , reviews the evidence on the benefits and risks of oral antiplatelet therapies, with a focus on balancing ischemic and bleeding risk to optimize patient outcomes.

Click here to read the supplement

Recommended Reading

Hypertensive disease of pregnancy linked to earlier mortality
MDedge Family Medicine
Heart disease risk soars in young adults with coronary calcium
MDedge Family Medicine
Atherosclerosis severity in diabetes can be predicted by select biomarkers
MDedge Family Medicine
Trials refine device therapy options for heart failure
MDedge Family Medicine
New ACC guidance on periprocedural management of anticoagulation in A-fib falls short
MDedge Family Medicine
AACE: Updated lipid guidelines include ‘extreme risk’ category
MDedge Family Medicine
Hypertension in SLE pregnancy: Is it lupus flare or preeclampsia?
MDedge Family Medicine
When to screen asymptomatic diabetics for CAD
MDedge Family Medicine
The two faces of mitral regurgitation
MDedge Family Medicine
Testosterone Trials’ cardiac, cognitive results disappoint
MDedge Family Medicine